First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report - Top-Institutions - MDSpire

First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report

  • By

  • Xiaoling Zhu

  • Yinan Yu

  • Wei Si

  • Jun Xu

  • July 14, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Shanghai Jiao Tong University School of Medicine
    Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai

    Key Differentiators

    • Oncology

  • #2

    Tianjin Medical University Cancer Institute and Hospital
    Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin

    Key Differentiators

    • Oncology

  • #3

    Zhongshan Hospital, Fudan University
    Zhongshan Hospital, Fudan University

    Shanghai, Shanghai

    Key Differentiators

    • Oncology

Original Source(s)

First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report

  • by Xiaoling Zhu, Yinan Yu, Wei Si, Jun Xu

  • July 14, 2026

Related Content

Integrating polyphenols and exercise in cancer prevention, treatment, and rehabilitation: cellular and molecular mechanisms linking the injury–recovery–musculoskeletal resilience axis

EUS-guided transmural treatment of afferent loop syndrome: a systematic review and meta-analysis

Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review